Ligand News and Research

RSS

Microneedle-embedded patch delivers cancer immunotherapy directly to melanoma

Biomedical engineering researchers at North Carolina State University and the University of North Carolina at Chapel Hill have developed a technique that uses a patch embedded with microneedles to deliver cancer immunotherapy treatment directly to the site of melanoma skin cancer. In animal studies, the technique more effectively targeted melanoma than other immunotherapy treatments.

25 Mar 2016

Value of PD-L1 testing in NSCLC debated

Two viewpoint articles published in JAMA Oncology provide opposing opinions on the benefit of testing for programmed death-ligand 1 expression in patients with non-small-cell lung cancer treated with checkpoint inhibitors.

18 Mar 2016

Molecular basis for tongue cancer progression: an interview with Dr Simona Principe

Head and neck cancers (HNC) are the sixth most common cancers worldwide, with approximately 600,000 new cases diagnosed every year.

From Beckman Coulter Life Sciences - Centrifugation 17 Mar 2016

Kanazawa University researchers identify molecular mechanism that links liver disease and obesity

Kanazawa University researchers find similarities in the impeded signalling between central insulin activity and glucose production in the liver for both obese mice and mice that have had the vagus nerve removed.

16 Mar 2016

Healthful hops compounds could help scientists develop medicines for cancer, inflammatory diseases

Hops, those little cone-shaped buds that give beer its bitter flavor, pack a surprisingly healthful punch. They are widely studied for their ability to halt bacterial growth and disease. Now, researchers report that they are close to synthesizing the healthful hops compounds in the lab. This advance could one day help scientists create medicines from these compounds without having to extract them from plants.

14 Mar 2016

CWRU researcher to customize tobacco mosaic virus to treat human cancers

A Case Western Reserve University researcher has been awarded more than $3 million in federal and foundation grants to turn common plant viruses into cancer sleuths and search-and-destroy emissaries.

10 Mar 2016

Johns Hopkins Greenberg Bladder Cancer Institute awards grants for 10 bladder cancer research projects

A study of obesity and related metabolic changes on bladder cancer incidence and deaths, and a plan to use stem cells to grow novel urinary tubes are among 10 research projects awarded funding by the Johns Hopkins Greenberg Bladder Cancer Institute.

7 Mar 2016

Modified protein appears to reverse liver fibrosis, cirrhosis in rats

A protein modified to increase the amount of time it circulates in the bloodstream appears to reverse liver fibrosis and cirrhosis in rats, according to results of a study led by Johns Hopkins researchers.

3 Mar 2016

More phase II success for CGRP migraine prevention strategy

Another antibody targeting the calcitonin gene-related peptide pathway has proved successful against episodic migraine in a phase II trial.

18 Feb 2016

Apogenix awarded €3 million grant to develop immuno-oncology candidate APG101 as personalized therapy

Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that it has received funding approval in the amount of €3 million from the German Federal Ministry of Education and Research for the so-called CancerMark project.

16 Feb 2016

UAB research reveals heterogonous population of leukemia stem cells

University of Alabama at Birmingham researchers have found a marker on blood cells that may help the most pressing problem in chronic myelogenous leukemia, or CML, today — an inability to get patients off treatment.

16 Feb 2016

Ageing 2016 summit to explore various aspects of processes, research on ageing and senescence

Ageing 2016 will be held from February 9 to 11, 2016 at Cineworld: The O2 Peninsula Square London SE10 0DX United Kingdom. The annual international summit will look at the various aspects of processes and research involved in ageing and senescence.

25 Jan 2016

PD-L1 inhibition well-tolerated, active in metastatic RCC

The programmed death-ligand 1 inhibitor atezolizumab has a favourable toxicity profile and shows anti-tumour activity in previously treated patients with metastatic renal cell carcinoma, according to phase Ia trial findings.

19 Jan 2016

Cornell researchers identify potent cancer-killing proteins that can kill tumors in bloodstream

Cornell researchers have discovered potent cancer-killing proteins that can travel by white blood cells to kill tumors in the bloodstream of mice with metastatic prostate cancer. The breakthrough study will be published Feb. 10 as the cover article in the Journal of Controlled Release.

13 Jan 2016

GPR119 could be a potential treatment target for nonalcoholic fatty liver disease

New research published in the January 2016 issue of The FASEB Journal suggests that the G-protein-coupled receptor 119 (GPR119) could be a viable treatment target for nonalcoholic fatty liver disease. This receptor has already been identified as a drug target for diabetes and obesity, and this report raises hopes that compounds that target GPR119 for diabetes or obesity might also work for non-alcoholic fatty liver disease.

12 Jan 2016

Using stem cells to tackle CNS disorders: an interview with Dr Stefano Pluchino

My laboratory’s long standing interest is the study of the signaling capabilities of stem cells, both under homeostatic conditions

From Beckman Coulter Life Sciences - Flow Cytometry 5 Jan 2016

TIGER-X study reviews efficacy of rociletinib therapy in patients with EGFR mutant-positive NSCLC

Oncology & Hematology Review, the peer-reviewed journal, has published a review highlighting recent data around rociletinib, an investigational therapy in patients with previously treated EGFR mutant-positive non-small cell lung cancer.

23 Dec 2015

TUM scientists develop small molecule that may allow future patient-specific treatment of cancer tumours

Integrins help cells communicate with and adapt to their environment. Also cancer cells depend on their properties to survive and spread throughout the body. Now scientists at the Technical University of Munich have successfully developed a small, highly active molecule that binds to a specific integrin which operates in many types of cancer.

21 Dec 2015

New way to antagonize human nuclear receptor

On Monday 7 December the journal Nature Communications published the research findings of Eindhoven University of Technology (TU/e), Merck Research Laboratories (Merck is known as MSD outside the US and Canada) and Leiden University concerning an entirely new way of antagonizing a human nuclear receptor.

8 Dec 2015

Interaction between two brain proteins has substantial effect on memory formation

In a new study that could have implications for future drug discovery efforts for a number of neurodegenerative diseases, scientists from the Florida campus of The Scripps Research Institute (TSRI) have found that the interaction between a pair of brain proteins has a substantial and previously unrecognized effect on memory formation.

20 Nov 2015